Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825832 | 0.81 | KDM4E (0.61) | SMN1; SMN2KMT2AMEN1KDM4ERAB9A | |
| SCHEMBL13105216 | 0.81 | KDM4E (0.65) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL20214047 | 0.80 | HDAC1 (0.51) | KDM4ERAB9ANPC1HDAC1HDAC2 | |
| SCHEMBL3334264 | 0.80 | CA1 (0.61) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL22761303 | 0.77 | KDM4E (0.73) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL12882390 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL1143313 | 0.76 | KDM4E (0.66) | SMN1; SMN2CSNK2A2CSNK2A1KDM4ERAB9A | |
| SCHEMBL28573287 | 0.75 | PIK3CD (0.60) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL11935946 | 0.74 | PIM1 (0.45) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 | |
| SCHEMBL3826842 | 0.74 | HDAC1 (0.44) | SMN1; SMN2KMT2AMEN1CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030072725-A1 | Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles | HAARMANN & REIMER GMBH (DE) | 2003-04-17 | — | — | US | claimed |
| US-20020128268-A1 | Use of 2-hydrazino-1,3-thiazoles as antioxidants | HAARMANN & REIMER GMBH (DE) | 2002-09-12 | — | — | US | claimed |
| EP-2089380-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER IP GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| CN-101541785-B | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4 -hydroxylase inhibitors | BAYER IP GMBH | 2014-03-12 | — | — | CN | disclosed |
| US-8524699-B2 | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20120264704-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2089380-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008049538-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-02 | — | — | WO | disclosed |
| US-20030072725-A1 | Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles | HAARMANN & REIMER GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128268-A1 | Use of 2-hydrazino-1,3-thiazoles as antioxidants | GPX1, LPO, GPX4 | SMN1; SMN2 3373/4885KMT2A 2412/4885MEN1 3618/4885 |
| US-20120264704-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | SMN1; SMN2 4495/4885KMT2A 804/4885MEN1 4453/4885 |
| US-20030072725-A1 | Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles | TYR, MITF, HDAC1 | SMN1; SMN2 4816/4885KMT2A 639/4885MEN1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.